13820-15-0

Basic information

• Product Name: Benzonitrile, 3-chloro-, N-oxide
• CAS NO: 13820-15-0
• Molecular Formula: C7H4ClNO
• Molecular Weight: 153.568
• Mol File: 13820-15-0.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: Benzonitrile, 3-chloro-, N-oxide(CAS DataBase Reference)
• NIST Chemistry Reference: Benzonitrile, 3-chloro-, N-oxide(13820-15-0)
• EPA Substance Registry System: Benzonitrile, 3-chloro-, N-oxide(13820-15-0)

Safety Data

• Hazardous Substances Data: 13820-15-0(Hazardous Substances Data)

Upstream product

• 587-04-2 m-Chlorobenzaldehyde 
• 34158-71-9 3-chlorobenzaldehyde oxime 
• 29203-59-6 3-chloro-N-hydroxybenzimidoyl chloride 
• 33341-68-3 N-Chloro-m-chlor-benzamid 

Downstream Products

• 144835-92-7 (3aR,6aS)-3-(3-Chloro-phenyl)-5-(3,5-dichloro-phenyl)-3a,6a-dihydro-pyrrolo[3,4-d]isoxazole-4,6-dione 
• 89047-06-3 3-(3-chlorophenyl)isoxazole 
• 1424394-75-1 C₁₂H₁₂ClNO₃ 
• 1171190-67-2 3-(3-chlorophenyl)-5-methyl-4-phenylisoxazole 
• 107524-50-5 3,3'-bis-(3-chloro-phenyl)-[5,5']biisoxazolyl 
• 107523-14-8 3-(3-chloro-phenyl)-3'-phenyl-[5,5']biisoxazolyl 
• 107519-50-6 3-(3-chloro-phenyl)-isoxazole-5-carboxylic acid anilide 
• 100517-43-9 3-(3-chlorophenyl)-1,2-oxazole-5-carboxylic acid 
• 86739-43-7 N-[2-[3-(3-Chloro-phenyl)-isoxazol-5-yl]-1-phenyl-eth-(Z)-ylidene]-N'-(4-nitro-phenyl)-hydrazine 
• 86739-44-8 N-[2-[3-(3-Chloro-phenyl)-isoxazol-5-yl]-1-phenyl-eth-(Z)-ylidene]-N'-phenyl-hydrazine 
• 26218-71-3 3,4-Bis(3-chlorophenyl)furoxan 
• 112853-61-9 3-(3-chlorophenyl)-5-hydroxy-2-isoxaline 

Relevant articles and documents

Dibenzazepine-linked isoxazoles: New and potent class of α-glucosidase inhibitors

α-Glucosidase inhibition is a valid approach for controlling hyperglycemia in diabetes. In the current study, new molecules as a hybrid of isoxazole and dibenzazepine scaffolds were designed, based on their literature as antidiabetic agents. For this, a series of dibenzazepine-linked isoxazoles (33–54) was prepared using Nitrile oxide-Alkyne cycloaddition (NOAC) reaction, and evaluated for their α-glucosidase inhibitory activities to explore new hits for treatment of diabetes. Most of the compounds showed potent inhibitory potency against α-glucosidase (EC 3.2.1.20) enzyme (IC50 = 35.62 ± 1.48 to 333.30 ± 1.67 μM) using acarbose as a reference drug (IC50 = 875.75 ± 2.08 μM). Structure-activity relationship, kinetics and molecular docking studies of active isoxazoles were also determined to study enzyme-inhibitor interactions. Compounds 33, 40, 41, 46, 48–50, and 54 showed binding interactions with critical amino acid residues of α-glucosidase enzyme, such as Lys156, Ser157, Asp242, and Gln353.

Cu(I)-Catalysis of One-Pot Synthesis of Some Novel Regioselective Isoxazole-Benzimidazole Hybrids and Their In Vitro Anti-Cancer Evaluation

Regioselective synthesis of some novel isoxazole-benzimidazole hybrids in high yields via Cu(I)-catalyzed tandem one-pot reaction of aromatic aldehydes with 1-prop-2-ynylbenzimidazole is developed. Structures of the synthesized compounds are confirmed by

Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors

3-(5-Chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6), a known selective cyclooxygenase-1 (COX-1) inhibitor, was used to design a new series of 3,4-diarylisoxazoles in order to improve its biochemical COX-1 selectivity and antiplatelet efficacy. Structure-activity relationships were studied using human whole blood assays for COX-1 and COX-2 inhibition in vitro, and results showed that the simultaneous presence of 5-methyl (or -CF3), 4-phenyl, and 5-chloro(-bromo or -methyl)furan-2-yl groups on the isoxazole core was essential for their selectivity toward COX-1. 3g, 3s, 3d were potent and selective COX-1 inhibitors that affected platelet aggregation in vitro through the inhibition of COX-1-dependent thromboxane (TX) A2. Moreover, we characterized their kinetics of COX-1 inhibition. 3g, 3s, and 3d were more potent inhibitors of platelet COX-1 and aggregation than P6 (named 6) for their tighter binding to the enzyme. The pharmacological results were supported by docking simulations. The oral administration of 3d to mice translated into preferential inhibition of platelet-derived TXA2 over protective vascular-derived prostacyclin (PGI2).